AELIX Therapeutics — Series A · €11.5M

Soon after its November 2015 spin-off from HIVACAT, AELIX closed an €11.5M ($12.7M) Series A led by Ysios Capital through Ysios BioFund II Innvierte, with Caixa Capital Risc and Johnson & Johnson Innovation – JJDC. The money was to take the HTI therapeutic HIV vaccine through a Phase 2 proof-of-concept trial. The capital increases for this round were still being registered in November 2017.